<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-21T16:55:32Z</responseDate><request verb="GetRecord" identifier="oai:www.repository.cam.ac.uk:1810/303391" metadataPrefix="uketd_dc">https://api.repository.cam.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:www.repository.cam.ac.uk:1810/303391</identifier><datestamp>2025-12-20T02:17:15Z</datestamp><setSpec>com_1810_224161</setSpec><setSpec>com_1810_256067</setSpec><setSpec>col_1810_224162</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>Genomic aberrations as determinants of immune infiltrates in high grade serous ovarian carcinoma</dc:title>
   <dc:identifier xsi:type="dcterms:DOI">10.17863/CAM.50479</dc:identifier>
   <dc:creator>Al-Khalidi, Sarwah</dc:creator>
   <uketdterms:advisor>Brenton, James</uketdterms:advisor>
   <dcterms:abstract>Despite increasing reports indicating the prognostic significance of immune cell abundance
in high grade serous ovarian cancer (HGSOC), mutational processes by which tumours gain
immunogenicity or develop immune evasion are yet to be identified. Mutational processes that
play a key role in HGSOC tumourigenesis leave imprints of copy-number aberrations (CNA) in
the patient’s genome. These CNA can be summarised into seven copy number (CN) signatures,
each associated with a specific mutational process. To identify mutational process associated
with determining the immune response to HGSOC, I investigated the correlation between CN
signatures and the density of key prognostic immune cells in a cohort of 172 HGSOC samples.
The exposure to signatures in each sample was previously quantified. I first developed two
multiplex IHC protocols against CD3, CD8, FOXP3 and CD20, and quantified the total, tumour
and stroma densities of CD3+, CD8+, CD8−, FOXP3+ and CD20+cells in the patient cohort
using HALO image analysis software. I also quantified the abundance of other immune cells
in the samples using gene expression data. I used linear mixed modelling to fit the immune
densities, and assessed the ability of CN signatures to predict the model. This revealed that the
presence of CN signature 6, associated with high genomic CN states, is inversely correlated
with all measures of immune cell densities, while the presence of homologous recombination
deficiency (HRD)-associated CN signature 7 correlates positively with immune cell abundance
(p > 0.05, ANOVA). Samples with a combination of absent CN signature 6 and present CN
signature 7 had the highest abundance of immune infiltrates. These results indicate that the
balance between high CN states and HRD is associated with determining the immune response
in HGSOC. Feature expansion of the immune markers analysed using gene expression data and
imaging mass cytometry will also be discussed.</dcterms:abstract>
   <uketdterms:institution>University of Cambridge</uketdterms:institution>
   <dcterms:issued>2020-02-25</dcterms:issued>
   <dc:type>Thesis</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <uketdterms:qualificationname>Doctor of Philosophy (PhD)</uketdterms:qualificationname>
   <dc:language>en</dc:language>
   <uketdterms:sponsor>Medimmune/ Astrazeneza</uketdterms:sponsor>
   <dcterms:isReferencedBy xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/handle/1810/303391</dcterms:isReferencedBy>
   <dc:identifier xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/bitstreams/7e6940fe-cd10-4425-a480-16adbb50177a/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">087916946e3a4d0dda0e27eecb957571</uketdterms:checksum>
   <dcterms:license>https://www.repository.cam.ac.uk/bitstreams/6f400c36-ea97-4509-a134-c24c283df2ab/download</dcterms:license>
   <uketdterms:checksum xsi:type="uketdterms:MD5">87eda9de84448d1f82354d60eee3eb5f</uketdterms:checksum>
   <dc:rights>https://www.rioxx.net/licenses/all-rights-reserved/</dc:rights>
   <dc:subject>Cancer</dc:subject>
   <dc:subject>Ovarian</dc:subject>
   <dc:subject>immune</dc:subject>
   <dc:subject>Immun-Oncology</dc:subject>
   <dc:subject>Oncology</dc:subject>
   <dc:subject>Genomic Aberration</dc:subject>
   <dc:subject>Copy number alterations</dc:subject>
</uketd_dc:uketddc>
</metadata></record></GetRecord></OAI-PMH>